Immune-Related Adverse Events and Efficacy - The More It Hurts, the Better It Works? - Reply

Jarushka Naidoo; Jiajia Zhang; Bairavi Shankar

doi:10.1001/jamaoncol.2021.0732

Immune-Related Adverse Events and Efficacy - The More It Hurts, the Better It Works? - Reply

Jarushka Naidoo, Jiajia Zhang, Bairavi Shankar

School of Medicine

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Pages (from-to)	945
Number of pages	1
Journal	JAMA Oncology
Volume	7
Issue number	6
DOIs	https://doi.org/10.1001/jamaoncol.2021.0732
State	Published - Jun 2021

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1001/jamaoncol.2021.0732

Cite this

@article{b6bcd4e40396434195e1e6f5d81af1ed,

title = "Immune-Related Adverse Events and Efficacy - The More It Hurts, the Better It Works? - Reply",

author = "Jarushka Naidoo and Jiajia Zhang and Bairavi Shankar",

note = "Funding Information: funding from Merck and AstraZeneca; consulting/advisory board roles for Merck, AstraZeneca, Bristol Myers Squibb, Roche, Takeda, Pfizer, and Daiichi Sankyo. No other disclosures were reported.",

year = "2021",

month = jun,

doi = "10.1001/jamaoncol.2021.0732",

language = "English (US)",

volume = "7",

pages = "945",

journal = "JAMA Oncology",

issn = "2374-2437",

publisher = "American Medical Association",

number = "6",

}

TY - JOUR

T1 - Immune-Related Adverse Events and Efficacy - The More It Hurts, the Better It Works? - Reply

AU - Naidoo, Jarushka

AU - Zhang, Jiajia

AU - Shankar, Bairavi

N1 - Funding Information: funding from Merck and AstraZeneca; consulting/advisory board roles for Merck, AstraZeneca, Bristol Myers Squibb, Roche, Takeda, Pfizer, and Daiichi Sankyo. No other disclosures were reported.

PY - 2021/6

Y1 - 2021/6

UR - http://www.scopus.com/inward/record.url?scp=85105166248&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85105166248&partnerID=8YFLogxK

U2 - 10.1001/jamaoncol.2021.0732

DO - 10.1001/jamaoncol.2021.0732

M3 - Letter

C2 - 33914013

AN - SCOPUS:85105166248

SN - 2374-2437

VL - 7

SP - 945

JO - JAMA Oncology

JF - JAMA Oncology

IS - 6

ER -

Immune-Related Adverse Events and Efficacy - The More It Hurts, the Better It Works? - Reply

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this